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Background: Variations in single nucleotide polymorphisms (SNPs) have been associated with enhanced drug
efficacy and toxicity in cancer therapy. SNP variations in the ErbB2 gene have been identified that alter the protein
sequence of the HER2-neu protein, but how these polymorphisms affect prognosis and response to HER2 targeted
therapy is unknown. We examined eleven ErbB2 SNPs that alter the HER2-neu amino acid sequence to determine
whether any of these particular polymorphisms were associated with increased trastuzumab cardiotoxicity in a
case–control study.
Methods: 140 subjects were enrolled from a single institution under Weill Cornell Medical College IRB protocol
#0804009734. Patients were eligible if they had histologically or cytologically proven HER2-neu positive breast
cancer and more than 3 months of trastuzumab therapy. Cases had either symptomatic CHF or a decline in LVEF
of 15% (or if the LVEF <55%, a decline in LVEF of 10%) that resulted in at least temporary discontinuation of
trastuzumab, whereas controls had no decline in their LVEF. Eleven ErbB2 single gene SNPs that resulted in an
alteration in the HER2-neu protein amino acid sequence were studied. Single gene SNP analysis was carried out
using SNP genotyping assays from genomic DNA obtained from peripheral blood or buccal swab.
Results: Only two of the ErbB2 SNPs (Ile 655 Val and Pro 1170 Ala) were found to have variation. There was no
association between codon 665 and cardiotoxicity; however the proline variant of amino acid 1170 was more likely
than the alanine variant to be found in cases with trastuzumab cardiotoxicity (35% of case patients as compared
to 17% of controls, p = 0.04). This association remained significant in multivariable analysis taking into account age,
race, and history of hypertension (adjusted OR = 2.60, 95% CI = 1.02, 6.62, p = 0.046).
Conclusions: The Her2/neu Pro 1170 Ala polymorphism can be used to identify a subset of patients who are at
increased risk of cardiotoxicity from trastuzumab therapy. Her2/neu single nucleotide polymorphisms may be
useful in conjunction with other biomarkers to risk stratify patients in order to optimize clinical management.
Keywords: Her2-neu, Breast cancer, Trastuzumab cardiotoxicity, Single nucleotide polymorphisms, Pro 1170 Ala
polymorphismBackground
Variations in single nucleotide polymorphisms (SNPs)
have been associated with enhanced drug efficacy and
toxicity in cancer therapy [1]. The monoclonal antibody
trastuzumab has provided a critical directed therapy that
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unless otherwise stated.breast cancer patients whose tumor overexpresses the
HER2-neu receptor [2]. Prior to the advent of trastuzu-
mab therapy, patients with HER2 positive tumors had
significantly worse prognosis, with decreased response
to chemotherapy, increased risk of relapse, and increased
incidence of brain metastases compared with patients
with HER2 negative tumors [3]. Although trastuzumab
is well tolerated, the major toxicity is cardiomyopathy,
with approximately 10% of patients developing asymp-
tomatic left ventricular ejection fraction (LVEF) declinel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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to <50%) and 4% developing signs of congestive heart
failure following treatment with trastuzumab as a single
agent [4]. From a meta-analysis of 10 randomized con-
trol trials including 11,882 patients with early stage and
metastatic breast cancer, trastuzumab therapy was asso-
ciated with a 7.5% risk of LVEF decrease and a 1.9% risk
of CHF. The risk of LVEF decline was 2.13-fold and
CHF was 4.19-fold compared with patients not receiving
trastuzumab [5]. When trastuzumab was used concur-
rently with anthracycline chemotherapy the risk of car-
diac dysfunction was 27% compared with 13% when a
non-anthracycline regimen was used [2,4]. The risk of
trastuzumab cardiotoxicity was shown to be further in-
creased in older women, women with a decreased EF
prior to starting trastuzumab therapy, and women on an
anti-hypertensive agent prior to starting trastuzumab [5].
The mechanism of trastuzumab cardiotoxicity is un-
known. HER2/neu has been shown to be essential in car-
diac myocytes in animal models. In mouse studies,
knockout of the ErbB2 gene is lethal and knockout of
ErbB2 in cardiac myocytes predisposes mice to dilated
cardiomyopathy in response to cardiac stress (including
exposure to anthracyclines) [6-8]. However, unlike the
ultra-structural changes in cardiac myocytes seen with
anthracyclines, including vacuolization and myocyte cell
death, cardiac biopsies after trastuzumab related cardiac
dysfunction showed no structural changes [9]. Whereas
anthracycline toxicity is dose-dependent and irreversible,
trastuzumab toxicity is not dose dependent and is re-
versible, and patients can often be re-treated with trastu-
zumab even after an initial LVEF decline if they are
placed on cardiac medications [3,9,10]. Interestingly, not
all targeted HER2 therapies have similar cardiotoxicity
profiles, with the small molecule dual EGFR and HER2
inhibitor lapatinib having much less cardiac toxicity than
trastuzumab (0.2% CHF and 1.4% asymptomatic cardiac
events) [9].
Single nucleotide polymorphisms (SNPs) are normal
variations in a gene sequence that may influence a drug’s
efficacy or toxicity. A current review of the Exome Vari-
ant Server (http://evs.gs.washington.edu/EVS) for ERBB2
recovered 67 missense SNPs, 47 of which are believed to
lead to significant protein alterations. To date the role of
these SNPs on both outcomes and response to therapy
in HER2 breast cancer is poorly understood [9]. The best
studied is the polymorphism at amino acid 655 in the
transmembrane domain of HER2-neu [11-13]. In 1039
patients with invasive HER2 positive breast cancer, the
Ile 655 Val polymorphism was found to be associated
with a 1.5-fold increase in HER2-neu expression and a
worse outcome [14]. The Ile/Val or Val/Val genotypes
have been associated with a 2-fold increase in risk of
breast cancer [15]. In a recent meta-analysis of 27 case–control studies of the Ile 655 Val polymorphism, the Val/
Val and Val/Ile phenotypes in patients not treated with tras-
tuzumab (n = 816) were associated with worse disease free
survival (hazard ratio [HR] = 1.5) and distant disease free
survival (HR = 1.9). However, when treated with trastuzu-
mab (n = 212) then the Val/Ile and Val/Val phenotypes were
associated with better disease free and distant disease free
survival [13]. In one study of 61 patients with advanced
breast cancer treated with trastuzumab, there was no asso-
ciation between the isoform and tumor response or sur-
vival, but appeared to be an association of the valine
polymorphism with cardiotoxicity [16]. From this early
evidence that polymorphisms in HER2/neu amino acid se-
quence may identify patients that are at risk for trastuzu-
mab cardiotoxicity, we conducted a case–control study to
evaluate more comprehensively whether any of 11 identi-




Patients were recruited from the Weill Cornell Breast
Oncology group between 2007 and 2012. All patients
had informed consent. This study was approved by the
Institutional Review Board (IRB) of Weill Cornell Med-
ical College under IRB protocol # 0804009734. Eligibility
criteria included either histologically (IHC 2-3+) or cyto-
logically (FISH amplification ratio ≥ 2) and history of
treatment with trastuzumab (in the adjuvant, metastatic,
or neoadjuvant setting). Twenty-nine of the 140 subjects,
defined as the case patients, had either symptomatic
CHF or a decline in LVEF of 15% (or if the LVEF <55%,
a decline in LVEF of 10%) that resulted in at least tem-
porary discontinuation of trastuzumab and controls had
to have received greater than 3 months of trastuzumab
therapy without a decline in their LVEF.
Sample processing
DNA was extracted from peripheral blood mononuclear
cells (PBMC) or in one case a buccal rinse. For whole
blood, PBMC were separated by ficoll gradient centrifu-
gation and PBMC DNA was extracted using phenol-
chloroform extraction and ethanol precipitation. DNA
pellets were dried and resuspended in Tris/EDTA (TE)
buffer. For the buccal rinse, the buccal cells were pel-
leted and DNA was extracted using the Puregene Buccal
Cell Kit following manufacturer’s instructions (Qiagen
Sciences, Valencia, CA). DNA concentrations were de-
termined using a Nano-Drop 1000 spectrophotometer
(NanoDrop Products, Willmington, DE).
SNP assay
SNP genotyping assays using validated sequence specific
primers and probes from Applied BioSystems (ABI,
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SNPs. Twenty nanograms of genomic DNA from each
patient were assayed in duplicate for each probe and pri-
mer set following manufacturer’s instructions. Assays
were performed using the ABI 7900HT real-time PCR
instrument. SNP calls were made using SDS 2.4 Allelic
Discrimination software (ABI, Foster City, CA). Samples
were run in duplicate for every SNP reaction. Thirty-
nine SNP sample PCR runs resulted in one of the two
SNP PCR reactions having a failed or undetermined re-
sult. Eight SNP sample PCR runs resulted in both SNP
PCR reactions having a failed result. The SNP PCR reac-
tions having an undetermined result in both PCR reac-
tions were repeated and a SNP call was able to be
determined for every SNP for every sample. No SNP
PCR runs resulted in a genotype discrepancy. The ob-
served genotype frequencies were in Hardy-Weinberg
equilibrium.
Statistical considerations
The frequency of individual ErbB2 SNPs has not been
well defined for most of the SNPs that have been identi-
fied. Sample size for the study was determined based on
the assumption that the frequency of Her2-neu SNPs in
controls was approximately 7.5%, which is the midpoint
of the I654 prevalence and the I655V homozygote
prevalence (which is in the 5-10% range). The most
information exists for the I655V polymorphism, whose
prevalence has been reported at between 4.9% - 10%.
The prevalence of three other polymorphisms is 6.5%
(I654V), 1.2% (W452C), and 10%-37% (P1170A). Assum-
ing the frequency of the Her2/neu SNP in controls was
7.5%, by genotyping approximately 35 cardiac cases and
105 non-cardiac controls (3:1 control:case ratio), the
study had 80% power (two-tailed alpha = 5%) to detect a
5-fold increase in a Her2/neu SNP genotype in cardiac
cases relative to non-cardiac controls. Descriptive statis-
tics (including mean, standard deviation, median, range,Table 1 Cases and controls are matched by age, race, and his
Number of patients







Baseline LVEF Median (range)
History of Hypertenson Yes
Nofrequency, and percent) were calculated to characterize
demographic and clinical factors in the case and con-
trols. The chi-square test was used to evaluate the asso-
ciation between 1) SNP variant status and case/control
status and 2) demographic/clinical factors (i.e., age, race,
hypertension status) and case/control status. Multivari-
able logistic regression analysis was used to examine the
association between Her2/neu SNP variant status and
cardiac toxicity (i.e., cases vs. controls), after controlling
for age, race, and hypertension status. Ninety-five per-
cent confidence intervals (95% CI) for the adjusted odds
ratios (OR) were calculated to assess the precision of the
obtained estimates. All p-values are two-sided with stat-
istical significance evaluated at the 0.05 alpha level. All ana-
lyses were performed using SAS Version 9.1 (SAS Institute,
Inc., Cary, NC).
Results
Clincopathologic characteristics of the patient population
140 patients with breast cancer treated with trastuzumab
were studied. There were 29 cases (patients who devel-
oped cardiotoxicity) and 111 controls (patients who did
not develop cardiotoxicity). The patients included in this
study had a median ejection fraction of 65% (range of
50% to 77%) prior to initiation of therapy. The cases and
controls had similar hypertension history (p = 0.89) with
16% of controls and 17% of cases having a history of
hypertension and the majority being normotensive
(Table 1). 79% of cases and 84% of controls were Cauca-
sian. There was a non-significant trend (p = 0.26) for
cases to be of black race compared to controls (13.8% vs
5.4%).
Frequency of SNP variation in population
The characteristics of the 11 HER2-neu SNPs examined are
shown in Table 2. Of these 11 SNPs, only two showed
variation among our study population, Rs1058808 and




39 (28%) 30 (27%) 9 (31%)
101 (72%) 81 (73%) 20 (69%)
140 (100%)
112 (80%) 93 (84%) 23 (79%)
18 (13%) 12 (11%) 2 (7%)
10 (7%) 6 (5%) 4 (14%)
65% (50-77%)
23 (16.4%) 18 (16%) 5 (17%)
117 (84%) 93 (84%) 24 (83%)
Table 2 Location, polymorphism, and amino acid change found in eleven HER2 SNPs studied
SNP Polymorphism Codon Amino acid change Protein domain
Rs4252633 G/T 452 Trp-Cys Ligand Binding
Rs1136201 A/G 655 Ile-Val Transmembrane
Rs34602395 G/T 703 Ser-Ile Tyrosine Kinase
Rs56366519 C/T 738 Ser-Ile Tyrosine Kinase
Rs28933369 A/G 776 Gly-Ser Tyrosine Kinase
Rs28933370 A/G 857 Asn-Ser Tyrosine Kinase
Rs28933368 A/G 914 Asp-Lys Tyrosine Kinase
Rs2172826 C/G 927 Pro-Arg Tyrosine Kinase
Rs1058808 C/G 1170 Pro-Ala Carboxy terminus
Rs55943169 A/C 1186 Ala-Asp Carboxy terminus
Rs36085723 A/G 1253 Val-Met Carboxy terminus
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ine at codon 655 in the transmembrane domain of the
HER2-neu protein (Table 2). The AA variant (Ile/Ile) was
present in 68% of the population, the AG variant (Ile/Val)
in 29% of the population, and the GG (Val/Val) variant in
3% of the population (Table 3). Rs1058808 is a change from
C to G that causes an amino acid change from proline to
alanine at codon 1170 in the carboxyterminus of the
HER2-neu protein. The CC variant (Pro/Pro) was present
in 20.7% of this patient population, the CG variant (Pro/
Ala) in 45.7% of the population, and the GG variant (Ala/
Ala) in 33.6% of the patient population. None of the SNPs
located in the kinase domain showed variation.
Association of Her2/neu polymorphisms with
symptomatic cardiomyopathy in the study population
There was no association observed between the codon
655 polymorphism and cardiotoxicity (p = 0.96, data not
shown). The CC (Pro/Pro) genotype at codon 1170
was associated with cardiotoxicity (34.5% of the cases
(10/29) as compared to 17.1% of the controls (19/111)
(p = 0.04)) (Table 4). SNP frequencies can vary by
ethnicity. We only had 10 black subjects and 14 Asian
subjects in our study and therefore did not carry out an as-
sociation analysis for each ethnicity separately. However, we
considered the question of whether a higher frequency of
black subjects might express the CC (Pro/Pro) genotype,
since we had found that there was a nonsignificant trend
toward black ethnicity being associated with cardiotoxicity.
The CC genotype occurred in 1 black subject (10% of the
black population), the GC genotype occurred in 5 subjects
(50%) and the GG genotype in 4 subjects (40%). From the
database http://evs.gs.washington.edu/EVS for the SNP
rs1058808 in African American subjects (n = 2203) the CC
genotype does occur more frequently (58.6% of subjects),
with the GG genotype occurring in 5.4% and the GC geno-
type occurred in 36% of subjects. However, within our smallblack population the CC genotype was not numerically in-
creased in black subjects. In a multivariable logistic regres-
sion model for predictors of case/control status, after
controlling for age, ethnicity, and previous history of hyper-
tension, only the 1170 polymorphism significantly predicted
case (cardiotoxicity) vs. control (no-cardiotoxicity) status
following trastuzumab therapy (p = 0.046, adjusted OR =
2.60; 95% CI = 1.02 to 6.62) (Table 5).
Discussion
We studied 140 women with HER2 positive breast can-
cer treated with trastuzumab. Based upon predefined
statistical considerations, we compared 29 cases with
cardiotoxicity to 111 controls. The cases and controls
were similar in age (27% of the controls and 31% of the
cases under the age of 50, p = 0.67), race (predominantly
Caucasian, 84% of the controls and 79% of the cases
with 11% of the controls and 8% of the cases Asian, p =
0.26), history of hypertension (16% of the controls and
17% of the cases, p = 0.89), and median LVEF at the start
of the study (Table 1). As hypertension, low LVEF, and
age are all factors that can contribute to trastuzumab
toxicity [9], the similarities of these factors between the
cases and controls suggest that the trastuzumab cardio-
toxicity can be associated with the SNP variants inde-
pendent of these other factors. Interestingly, there was a
non-significant trend suggesting that case patients may
be more likely to be of black race compared to controls
(Table 1, 13.8% of the cases and 5.4% of the controls).
However, the small sample size is too low to make
reliable inferences, and these results should be further
addressed in larger studies which include a higher pro-
portion of black subjects.
Of the 11 ErbB2 SNPs studied that caused HER2-neu
protein amino acid variations, only two, corresponding
to Ile 655 Val and Pro 1170 Ala, were found to have
variation among the ethnically mixed population with
Table 3 Polymorphism variation in the 11 HER2 SNPs
Rs4252633 Rs1136201 Rs34602395 Rs56366519 Rs28933369 Rs28933370 Rs28933368 Rs2172826 Rs1058808 Rs55943169 Rs36085723
Geno n Geno n Geno n Geno n Geno n Geno n Geno n Geno n Geno n Geno n Geno n
TT 0 AA 95 GG 140 TT 140 GG 140 AA 140 GG 140 CC 140 CC 29 CC 138 AA 0
TG 0 AG 41 GT 0 CT 0 AG 0 AG 0 AG 0 CG 0 CG 64 AC 2 AG 0
GG 140 GG 4 TT 0 CC 0 AA 0 GG 0 GG 0 GG 0 GG 47 AA 0 GG 140
Tot 140 Tot 140 Tot 140 Tot 140 Tot 140 Tot 140 Tot 140 Tot 140 Tot 140 Tot 140 Tot 140















Pro/Pro 19 (17.1%) 10 (34.5%)
Pro/Ala or Ala/Ala 92 (82.9%) 19 (65.5%)
p = 0.04.
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655 Val polymorphism (Rs1136201) there were 68% AA
(Ile/Ile), 29% AG (Ile/Val), and 3% GG (Val/Val)
(Table 3). These results are similar to the published re-
sults of the distribution Ile 655 Val polymorphism. For
example in one study there was 72% Ile/Ile, 26% Val/Ile,
and 2% Val/Val [13]. The Ile 655 Val polymorphism is
located in the transmembrane domain of the HER2-neu
protein (Table 2) and has been suggested to increase the
dimerization of the receptor thus increasing its expres-
sion [17]. In contrast with a previous report of an associ-
ation of the Ile 655 Val polymorphism with increased
rates of congestive heart failure [16], in our study the Ile
655 Val polymorphism was not associated with congest-
ive heart failure. This difference may be due to the larger
sample size in our study (140 subjects with 29 cases of
cardiotoxicity) compared to the previous study (61 sub-
jects with 5 cases of cardiotoxicity), or to differences in
cardiotoxicity definition or to differences in patient
population characteristics.
Instead we found that the Pro 1170 Ala polymorphism
was associated with trastuzumab cardiomyopathy. The
Pro/Pro genotype was present more frequently in the
cases (10/29 patients, 34.5%) than the controls (19/
111 or 17.1%) (Table 4). This association held up in
multivariable analysis when controlling for age, race,
and hypertension status. The Pro/Pro genotype was
independently associated with cases who developed
cardiotoxicity as compared to the either the Pro/Ala
or Ala/Ala genotype (adjusted OR = 2.60, p = 0.046,
Table 5). However, because we also had explored







Pro/Pro 0.046 0.385 0.151 0.983
Age 0.885 0.932 0.357 2.43
Race 0.51 1.426 0.496 4.095
Hypertension 0.75 1.182 0.376 3.713
Pro/Pro (referent = Ala/Ala or Ala/Pro).and GC vs other. (p = 0.17), the alpha level should be
corrected for multiple comparisons. The new multiple
comparison- adjusted alpha level would be 0.017
(0.05/3). Thus, after adjustment for multiple compari-
sons, our result would not be significant and therefore
replication of the observed findings is definitely re-
quired from future studies.
The Pro1170 Ala SNP, along with other biomarkers
such as micro RNA and troponin levels [9], could ultim-
ately be used to stratify patients into high and low risk
subsets so that clinical management could be tailored to
minimize the risk of cardiotoxicity. This is an important
problem because when trastuzumab is discontinued due
to cardiac toxicity, it deprives patients of this life-
prolonging drug. Overall our study has the limitation
that it is a single institution study. These results should
be confirmed with larger sample sizes, preferably with
inclusion of more minority subjects.
Compared with the Ile 655 Val polymorphism, the Pro
1170 Ala polymorphism has been less well studied. In
the only study evaluating breast cancer and the Pro1170
Ala polymorphism that we could find, it was reported
that the Pro1170 Ala polymorphism did not correlate
with increased breast cancer risk [14]. Amino acid codon
1170 is located at the carboxydomain of the Her2-neu
receptor and is not part of the trastuzumab binding site,
the ligand binding domain, or the heterodimerization
domain. The carboxydomain contains tyrosine resi-
dues that are phosphorylation sites for the kinase.
Both proline and alanine have non-polar side chains
but proline has a secondary amide structure which can
allow more stable hydrogen binding of nearby amino
acids [18]. How this could alter downstream signaling
and lead to increased trastuzumab associated cardio-
toxicity is unclear.Conclusion
The Her2/neu polymorphism Pro 1170 Ala is associated
with a 2.6-fold increased risk of cardiotoxicity in patients
with HER2-neu positive breast cancer treated with
trastuzumab. This result suggests that Her2/neu single
nucleotide polymorphisms may be useful in conjunc-
tion with other biomarkers to risk stratify patients into
those who might benefit from early institution of car-
diac medications or who might be considered for non-
anthracycline containing chemotherapy regimens in
order to avoid cardiotoxicity.
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